Oncologic and reproductive outcomes after fertility sparing surgery in young women with malignant ovarian germ cell tumors

Objective: This study evaluated the oncologic and obstetric outcomes after fertility-sparing surgery (FSS) in young patients with malignant ovarian germ cell tumors (MOGCTs). Methods: The medical records of women aged ≤40 years who underwent FSS for MOGCTs at our institution between July 2002 and December 2018 were retrospectively reviewed. FSS was defined as the preservation of the uterus and at least one adnexa. Results: Forty-four patients were included in this study. The median age of the patients was 22 years (range, 7–39 years). FIGO stage I (81.8%) was the most common, and stage II (6.8%), III (9.1%) and IV (2.3%) was also present. Twenty-nine patients (65.9%) received adjuvant chemotherapy with bleomycin, etoposide, and cisplatin (BEP) after a surgery. During a median follow-up period of 62 months (range, 7–185), four patients (9.1%) had a recurrence. Of these four patients, two with dysgerminoma had recurrences at paraaortic lymph nodes and two with immature teratomas had recurrences at the remaining ovary. Thirty-seven patients (88.1%) had regular menstruation. Of fourteen women desiring pregnancy, twelve achieved the term delivery of twelve singleton pregnancies. The pregnancy and live birth rates were 85.7%and 100%, respectively. Conclusions: FSS with or without following BEP chemotherapy is an appropriate option for young women with MOGCTs who wish to preserve their fertility.

Malignant ovarian germ cell tumor; Fertility-sparing surgery; Oncologic out-come; Obstetric outcome

[1] Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, et al. Incidence and survival rates for female malignant germ cell tumors. Obstetrics and Gynecology. 2006; 107: 1075–1085.

[2] Arora RS, Alston RD, Eden TOB, Geraci M, Birch JM. Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003. Cancer. 2012; 118: 4290–4297.

[3] Chan JK, Tewari KS, Waller S, Cheung MK, Shin JY, Osann K, et al. The influence of conservative surgical practices for malignant ovarian germ cell tumors. Journal of Surgical Oncology. 2008; 98: 111–116.

[4] Low JJ, Ilancheran A, Ng JS. Malignant ovarian germcell tumours. Best Practice & Research Clinical Obstetrics & Gynaecology. 2012; 26: 347–355.

[5] Young JL Jr, Cheng WX, Roffers SD, Howe HL, Correa C, Weinstein R. Ovarian cancer in children and young adults in the United States, 1992–1997. Cancer. 2003; 97: 2694–2700.

[6] Abu-Rustum NR, Aghajanian C. Management of malignant germ cell tumors of the ovary. Seminars in Oncology. 1998; 25: 235–242.

[7] Brown J, Friedlander M, Backes FJ, Harter P, O’Connor DM, de la Motte Rouge T, et al. Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. International Journal of Gynecological Cancer. 2014; 24: S48–S54.

[8] Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study–Pediatric Oncology Group 9049 and Children’s Cancer Group 8882. Journal of Clinical Oncology. 2004; 22: 2691–2700.

[9] Scully RE, Sobin LH, Serov SF. Histological typing of ovarian tumours (pp. 136). 2nd ed. New York: Springer Science & Business Media. 1999.

[10] Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecologic Oncology. 2014; 133: 401–404.

[11] Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) ter-atoma of the ovary. A clinical and pathologic study of 58 cases. Cancer. 1976; 37: 2359–2372.

[12] Park J, Kim D, Suh D, Kim J, Kim Y, Kim Y, et al. Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecologic Oncology. 2017; 145: 513–518.

[13] Mahdi H, Swensen RE, Hanna R, Kumar S, Ali-Fehmi R, Semaan A, et al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. British Journal of Cancer. 2011; 105: 493–497.

[14] Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstetrics & Gynecology. 2003; 101: 251–257.

[15] Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, et al. Reproductive and sexual function after platinumbased chemotherapy in long-term ovarian germ cell tumor sur-vivors: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2007; 25: 2792–2797.

[16] Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, et al. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the “cisplatin era”. Gynecologic Oncology. 2015; 136: 224–229.

[17] Park J, Kim D, Suh D, Kim J, Kim Y, Kim Y, et al. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors. Gynecologic Oncology. 2015; 137: 418–422.

[18] Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. Journal of Clinical Oncology. 1990; 8: 715–720.

[19] Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. Journal of Clinical Oncology. 1994; 12: 701–706.

[20] Lauritsen J, Mortensen MS, Kier MGG, Christensen IJ, Agerbaek M, Gupta R, et al. Renal impairment and late toxicity in germcell cancer survivors. Annals of Oncology. 2015; 26: 173–178.

[21] Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Olden-burg J, et al. Testicular cancer survivorship: research strategies and recommendations. Journal of the National Cancer Institute. 2010; 102: 1114–1130.

[22] Marina NM, Cushing B, Giller R, Cohen L, Lauer SJ, Ablin A, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: a pediatric oncology group/children’s cancer group intergroup study. Journal of Clinical Oncology. 1999; 17: 2137–2143.

[23] Cushing B, Giller R, Ablin A, Cohen L, Cullen J, Hawkins E, et al. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children’s cancer group. American Journal of Obstetrics and Gynecology. 1999; 181: 353–358.

[24] Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, et al. Surveillance after initial surgery for pediatric and adolescent girls with stage i ovarian germ cell tumors: report from the Children’s Oncology Group. Journal of Clinical Oncology. 2014; 32: 465–470.

[25] Park J, Kim D, Suh D, Kim J, Kim Y, Kim Y, et al. Outcomes of surgery alone and surveillance strategy in young women with stage I malignant ovarian germ cell tumors. International Journal of Gynecologic Cancer. 2016; 26: 859–864.